Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins: A case-control study

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 3, 2012, Pages 314-319

  Moulis, Guillaume ^a   Sailler, Laurent ^a   Sommet, Agnès ^a   Lapeyre Mestre, Maryse ^a   Montastruc, Jean Louis ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Angiotensin receptor antagonists; Angiotensin converting enzyme inhibitors; Intravenous immunoglobulins; Pharmacovigilance; Renal failure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMMUNOGLOBULIN G; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SUCROSE; THIAZIDE DIURETIC AGENT;

ACUTE KIDNEY FAILURE; ADULT; AGE; AGED; ANURIA; ARTICLE; BODY WEIGHT; CASE CONTROL STUDY; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETES MELLITUS; DRUG EXPOSURE; FEMALE; GENDER; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY BLOOD FLOW; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OLIGURIA; PREDICTOR VARIABLE; PRIORITY JOURNAL; REFERENCE DATABASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR;

ACUTE KIDNEY INJURY; AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CASE-CONTROL STUDIES; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFUSIONS, INTRAVENOUS; KIDNEY FUNCTION TESTS; MALE; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SUCROSE; TIME FACTORS;

EID: 84858241535     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2253     Document Type: Article

References (22)

1. Food and Drug Administration. Dear doctor letter important drug warning - potential risk of acute renal failure reported to be associated with administration of immune globulin intravenous (human). September 1999. (accessed 1 January 2011).
2. Peyrade F, Passeron C, Taillan B, Dujardin P. Acute renal failure due to immunoglobulins. Rev Med Interne 1998; 19: 746-747.
3. Agence Française de Sécurité Sanitaire des Produits de Santé. Risques d'insuffisance rénale liée à l'utilisation d'immunoglobulines intra-veineuses. December 2006. (accessed 1 January 2011).
4. Bégaud B, Evreux JC, Jouglard J, Lagier G. Imputation of the unexpected or toxic effects of drugs. actualization of the method used in France. Therapie 1985; 40: 111-118.
5. Moore N, Noblet C, Kreft-Jais C, et al. French Pharmacovigilance Database system: examples of utilisation. Therapie 1995; 50: 557-562.
6. Klein M, Kaminsky P, Duc M. High dose intravenous immunoglobulins in therapeutic arsenal in autoimmune and systemic diseases. Therapie 1993; 48: 97-103.
7. Orbach H, Katz U, Sherer Y, Shoenfeld Y. Intravenous immunoglobulin: adverse effects and safe administration. Clin Rev Allergy Immunol 2005; 29: 173-184.
8. Brannagan TH, Nagle KJ, Lange DJ, Rowland LP. Complications of intravenous immune globulin treatment in neurologic disease. Neurology 1996; 47: 674-677.
9. Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney--a two-edged sword. Semin Arthritis Rheum 2004; 34: 593-601.
10. Chapman SA, Gilkerson KL, Davin TD, Pritzker MR. Acute renal failure and intravenous immune globulin: occurs with sucrose-stabilized, but not with d-sorbitol-stabilized, formulation. Ann Pharmacother 2004; 38: 2059-2067.
11. Renal insufficiency and failure associated with immune globulin intravenous therapy--united states, 1985-1998. MMWR Morb Mortal Wkly Rep 1999; 48: 518-521.
12. Gras V, Andréjak M, Decocq G. Acute renal failure associated with intravenous immunoglobulins. Pharmacoepidemiol Drug Saf 1999; 8(1): S73-S78.
13. Sati HI, Ahya R, Watson HG. Incidence and associations of acute renal failure complicating high-dose intravenous immunoglobulin therapy. Br J Haematol 2001; 113: 556-557.
14. Rault R, Piraino B, Johnston JR, Oral A. Pulmonary and renal toxicity of intravenous immunoglobulin. Clin Nephrol 1991; 36: 83-86.
15. Kiski D, Stepper W, Brand E, Breithardt G, Reinecke H. Impact of renin-angiotensin-aldosterone blockade by angiotensin-converting enzyme inhibitors or at-1 blockers on frequency of contrast medium-induced nephropathy: a post-hoc analysis from the dialysis-versus-diuresis (DVD) trial. Nephrol Dial Transplant 2010; 25: 759-764.
16. Cirit M, Toprak O, Yesil M, et al. Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron Clin Pract 2006; 104: c20-c27.
17. Kini AS, Mitre CA, Kamran M, et al. Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. Am J Cardiol 2002; 89: 999-1002.
18. Dangas G, Iakovou I, Nikolsky E, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005; 95: 13-19.
19. Akram AR, Singanayagam A, Choudhury G, et al. Incidence and prognostic implications of acute kidney injury on admission in patients with community-acquired pneumonia. Chest 2010; 138: 825-832.
20. Bentley ML, Corwin HL, Dasta J. Drug-induced acute kidney injury in the critically ill adult: recognition and prevention strategies. Crit Care Med 2010; 38: S169-S174.
21. Arora P, Rajagopalam S, Ranjan R, et al. Preoperative use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers is associated with increased risk for acute kidney injury after cardiovascular surgery. Clin J Am Soc Nephrol 2008; 3: 1266-1273.
22. Rosenstock JL, Bruno R, Kim JK, et al. The effect of withdrawal of ace inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol 2008; 40: 749-755.